Vaccines and Antibodies

Through this initiative, our strategy is to pursue multiple avenues simultaneously, including developing active and passive vaccination platforms. Our scientists will interrogate the immune response to the virus in people with moderate and severe disease to understand how the body naturally clears SARS-CoV-2. We will identify the difference between a good immune response (that clears infection) and a bad immune response (that makes people more unwell) by developing and utilising neutralisation assays. For active immunisation, we will generate virus like particles (VLPs) that contain pieces of the SARS-CoV-2.